Kura Oncology (KURA) Competitors $5.54 -0.42 (-7.05%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.78 +0.25 (+4.42%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. IRON, AGIO, TWST, CGON, HRMY, DNLI, MESO, OCUL, BEAM, and VCELShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), CG Oncology (CGON), Harmony Biosciences (HRMY), Denali Therapeutics (DNLI), Mesoblast (MESO), Ocular Therapeutix (OCUL), Beam Therapeutics (BEAM), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Its Competitors Disc Medicine Agios Pharmaceuticals Twist Bioscience CG Oncology Harmony Biosciences Denali Therapeutics Mesoblast Ocular Therapeutix Beam Therapeutics Vericel Disc Medicine (NASDAQ:IRON) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Do analysts rate IRON or KURA? Disc Medicine currently has a consensus price target of $95.73, suggesting a potential upside of 64.96%. Kura Oncology has a consensus price target of $24.50, suggesting a potential upside of 342.24%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is IRON or KURA more profitable? Disc Medicine's return on equity of -27.75% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -27.75% -25.64% Kura Oncology N/A -52.32%-29.59% Does the media favor IRON or KURA? In the previous week, Kura Oncology had 2 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Kura Oncology and 7 mentions for Disc Medicine. Kura Oncology's average media sentiment score of -0.19 beat Disc Medicine's score of -0.19 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of IRON or KURA? 83.7% of Disc Medicine shares are held by institutional investors. 3.6% of Disc Medicine shares are held by company insiders. Comparatively, 6.4% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better valuation and earnings, IRON or KURA? Disc Medicine has higher earnings, but lower revenue than Kura Oncology. Disc Medicine is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$109.36M-$3.92-14.80Kura Oncology$53.88M8.92-$173.98M-$2.26-2.45 Which has more volatility and risk, IRON or KURA? Disc Medicine has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. SummaryDisc Medicine and Kura Oncology tied by winning 7 of the 14 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$480.87M$2.99B$5.47B$9.71BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-2.4517.3230.1124.69Price / Sales8.92318.76453.43114.20Price / CashN/A40.7324.8428.01Price / Book1.048.888.515.76Net Income-$173.98M-$54.75M$3.27B$267.05M7 Day Performance-12.34%-2.07%4.58%3.13%1 Month Performance-11.78%1.81%0.87%1.27%1 Year Performance-70.80%8.71%36.20%22.83% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology3.4457 of 5 stars$5.54-7.0%$24.50+342.2%-70.8%$480.87M$53.88M-2.45130News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeIRONDisc Medicine3.1763 of 5 stars$59.79+1.4%$95.73+60.1%+34.7%$2.04BN/A-15.2530Earnings ReportAGIOAgios Pharmaceuticals4.2594 of 5 stars$36.16+3.3%$56.33+55.8%-18.2%$2.03B$36.50M3.29390High Trading VolumeTWSTTwist Bioscience3.4572 of 5 stars$30.21-10.3%$50.40+66.8%-41.7%$2.02B$312.97M-9.30990Trending NewsEarnings ReportHigh Trading VolumeCGONCG Oncology1.572 of 5 stars$26.09-0.8%$55.30+112.0%-26.1%$2.01B$1.14M-17.2861News CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeHRMYHarmony Biosciences4.6153 of 5 stars$35.54+3.3%$51.00+43.5%+1.0%$1.98B$714.73M13.56200Trending NewsEarnings ReportAnalyst DowngradeAnalyst RevisionDNLIDenali Therapeutics4.2115 of 5 stars$14.44+7.4%$33.85+134.4%-37.7%$1.95B$330.53M-5.41430Positive NewsMESOMesoblast1.5433 of 5 stars$15.43+1.7%$18.00+16.7%+143.6%$1.94B$5.90M0.0080Positive NewsOCULOcular Therapeutix3.6278 of 5 stars$12.35+3.6%$17.33+40.4%+46.4%$1.90B$63.72M-10.74230Earnings ReportAnalyst RevisionBEAMBeam Therapeutics2.5402 of 5 stars$19.12+1.5%$48.75+155.0%-28.0%$1.89B$63.52M-4.15510Trending NewsEarnings ReportAnalyst RevisionVCELVericel2.2473 of 5 stars$37.58+5.5%$59.86+59.3%-20.5%$1.80B$237.22M313.19300 Related Companies and Tools Related Companies IRON Alternatives AGIO Alternatives TWST Alternatives CGON Alternatives HRMY Alternatives DNLI Alternatives MESO Alternatives OCUL Alternatives BEAM Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale